The rise of Viagra initially sparked a period of growth for pharma, however recent shifts present a murky outlook for shareholders. Off-patent alternatives are eroding revenue, and ongoing legal battles add more https://owainlqwg387796.blogginaway.com/41938233/the-blue-pill-and-big-pharma-a-risky-play